

**Regional Training Course on PET/CT in Oncology.  
(RER-6.035)**

**Riga and Liepaja (Latvia), October 3rd- 6th, 2016**

**Venue:** Nuclear Medicine Centre, Gardenes Street 13, Riga, LATVIA

*(NOTE: Learning objectives are located immediately below the title of the presentation in brown colour)*

**PROGRAM**

**Monday, October 3rd, 2016**

09.00–09.30 Welcome and presentation of participants

09.30–09.45 Presentation of the Training Course

09.45–10.15 Pre-course evaluation (multiple-choice test)

10.15–11.00 Oncology in the era of PET/CT (Dace Baltima)

*Recognize the changes that the introduction of PET/CT has had in the daily management of the cancer patient.*

*Understand the importance of accurate medical imaging in the clinical decision making.*

***11.00–11.15 Coffee break***

11.15–11.45 PET/CT: What the haematologist expect (Sandra Lejniece)

*Describe the medical imaging needs from the haematologist point of view.*

*Recognize the advantages and limitations that FDG-PET/CT may have in haematology.*

11.45–12.20 PET/CT in Oncology: an evidence based approach (HW Hendel)

*Understand the different scientific aspects that affect the quality of evidence.*

*Recognize the four steps in EBM*

*Identify the difficulties that may be encountered in determining the true accuracy of a PET/CT study.*

***12.20–13.30 Lunch***

- 13.30–14.00 PET/CT imaging of head & neck cancer (M.J. Garcia-Velloso)  
Identify the main indications for PET/CT in head and neck cancer.  
Understand the value of FDG-PET/CT in comparison with other imaging modalities in head and neck cancer.
- 14.00–14.30 PET/CT imaging of lung cancer (M. Stokkel)  
Recognize the specific indications of PET/CT in the management of lung cancer in comparison with other imaging modalities.  
Describe the value of PET/CT for prognostication of lung cancer.
- 14.30–15.10 IAEA activities in Nuclear Medicine. (R. Nuñez)  
Understand the role of the IAEA in the promotion of Nuclear Medicine in developing countries.  
Describe the different online educational resources available to Nuclear Medicine professionals from the IAEA web portal.

***15.10–15.30 Coffee break***

- 15.30–16.00 PET/CT imaging of lymphoma (HW Hendel)  
Describe the current criteria for assessment of response to therapy with PET/CT imaging in lymphoma.  
Enumerate for which types of lymphomas FDG-PET/CT has a lower diagnostic yield.
- 16.00–16.45 PET/CT in breast cancer (M. Stokkel).  
Recognize the main indications of FDG-PET/CT in breast cancer.  
Identify non-FDG PET tracers with recognized value if breast cancer imaging.
- 16.45–17.00 Questions/Comments
- 17.30– Welcome Reception

## **Tuesday, October 4rd, 2016**

- 08.30–09.30 SPECT/CT and PET/CT of bone diseases (HW Hendel)  
Describe the current role of PET/CT in bone disease.  
Identify the main imaging characteristics of bone disease in PET.
- 09.30–10.00 PET/CT imaging in multiple myeloma (M.J. Garcia-Velloso)  
Enumerate the advantages of PET/CT imaging for multiple myeloma.  
Describe the main indications for PET/CT in multiple myeloma.
- 10.00–10.30 PET/CT in Thyroid cancer (M. Stokkel)  
Summarize the main indications for PET/CT in thyroid cancer.  
Describe the correct patient preparation and imaging protocol with PET/CT in thyroid cancer.
- 10.30–11.00 Coffee break**
- 11.00–11.40 PET/CT in prostate cancer (R. Nuñez)  
Identify the different radiopharmaceuticals with clinical value in prostate cancer imaging.  
Enumerate the main indications for PET/CT imaging in prostate cancer.
- 11.40–12.20 PET/CT in therapy follow up (M. Stokkel)  
Describe the advantages of FDG-PET/CT for therapy follow up in comparison with other imaging modalities.  
Enumerate the differences between RECIST and PERCIST.
- 12.20–13.30 Lunch**
- 13.30–14.15 PET/CT imaging of gynaecologic malignancies (HW Hendel).  
Outline the main indications for PET/CT in gynaecologic malignancies.  
Identify the complementary role of PET/CT with other imaging modalities.
- 14.15–15.00 PET/CT and planning of radiation therapy (M.J. Garcia-Velloso)  
Describe the role of PET/CT for radiation therapy planning.  
Understand the correct imaging protocol with PET/CT for RT planning.
- 15.00–15.40 PET/CT in Neuroendocrine tumours (M. Stokkel)  
Identify the advantages of PET/CT imaging with new radiopharmaceuticals in these group of patients.  
Understand the concept of theranostics.
- 15.40–17.00 Visit to the Nuclear Medicine department and PET/CT centre, Riga

## **Wednesday, October 5th, 2016**

- 08.30–09.15 PET/CT in colorectal and gastrointestinal cancers (HW Hendel)  
Enumerate the main indications for FDG-PET/CT in different gastrointestinal cancers.  
Understand the limitations of FDG-PET/CT in this disorders, and propose alternative imaging techniques.
- 09.15–09.45 Hybrid imaging of the heart (M.J. Garcia-Velloso)  
Summarize the main indications of cardiac PET/CT.  
Describe the patient preparation and imaging protocols for hybrid imaging of the heart
- 09.45–10.15 PET/CT imaging in melanoma (HW Hendel)  
Recognize the main indications of PET/CT in the management of melanoma patients.  
Understand the roll of PET/CT in the risk stratification, prognostication and follow up of melanoma.

### ***10.15–10.40 Coffee break***

- 10.40–11.20 Pitfalls in FDG PET/CT imaging of the chest (M.J. Garcia-Velloso)  
Describe the main pitfalls that can be encountered in PET/CT imaging of the chest.  
Examine a given PET/CT of the chest and make appropriate diagnostic interpretation.
- 11.20–12.10 PET/CT new radiopharmaceuticals in Oncology (M. Stokkel)  
Identify the pathologic conditions for which the new radiopharmaceuticals can provide with the biggest clinical value.  
Recognize different imaging protocols for PET/CT imaging with new radpharmaceuticals

### ***12.10–13.30 Lunch***

- 13.30–15.00 *Presentation/Review of interesting and challenging cases.* (All participants)
- 15.15– Transfer to Liepaja

**Thursday, October 6th, 2016 (Baltic School of Radiology)**

- 10.00–10.10 Introduction (M. Kalnina, M.Radzina and R. Nuñez)
- 10.10–10.40 Methodological aspects in FDG-PET/CT imaging. (M.J. Garcia-Velloso)  
Understand the importance of good patient preparation for PET/CT imaging.  
Recognize the main pitfalls that can be seen in cases with poor patient preparation and inadequate imaging protocol.
- 10.40–11.10 Basics of interpretation of FDG-PET/CT imaging (HW Hendel).  
Identify the anatomical structures seen in a normal FDG-PET scan.  
Recognize the added diagnostic value of CT imaging in the interpretation of PET/CT studies.
- 11.10–11.40 When to use PET/CT in Oncology. Evidence base practice (Donatas Vajauskas)  
Describe the main current indications of FDG-PET/CT in oncology.  
Recognize the limitations of FDG-PET/CT for certain types of cancer.
- 11.40–12.10 Imaging of prostate cancer with choline PET/CT in view of new European guidelines (Miroslaw Dziuk)  
List the main indications for PET/CT imaging in prostate cancer.  
Recognize the limitations of FDG and choline PET/CT in prostate cancer imaging.

***12.10–13.10 Lunch***

- 13.10–15.00 Cases on PET/CT (IAEA experts)  
Recognize the different PET radiopharmaceuticals used in PET/CT imaging.  
Describe the main pitfalls seen with PET/CT in oncology.

***15.00–15.15 Coffee break***

- 15.15–15.45 Functional MRI vs PET/CT similarities and differences (M. Kalnina/E.Olmane)  
Describe different forms of functional MRI which can complement PET/CT imaging.  
Enumerate the advantages and limitations of PET/CT in comparison with MRI.
- 15.45–16.00 Conclusions (M. Kalnina and R. Nuñez)
- 16.00–16.30 Post course evaluation
- 16.30–17:00 Resolving MCQ, Certificate Presentation, and Closure of the Course

**Friday, October 7th and Saturday October 8th 2016. Baltic Congress of Radiology**

**Faculty members of the course**

Dr. Rodolfo Núñez Miller  
Nuclear Medicine physician  
International Atomic Energy Agency.  
Vienna International Centre, PO Box 100  
1400 Vienna  
Austria  
Tel: +43(1) 2600-21673  
e-mail: [R.Nunez-Miller@iaea.org](mailto:R.Nunez-Miller@iaea.org)

Dr. Marika Kalnina  
Head of Nuclear Medicine Department  
Nuclear Medicine Centre, Ltd  
Gardenes 13, Riga, Latvia, LV-1002  
Tel.: +37126313558  
e-mail: [marika.kalnina@gmail.com](mailto:marika.kalnina@gmail.com)

Dr. Marcel Stokkel  
Nuclear Medicine department  
The Netherlands Cancer Institute  
Amsterdam  
Netherlands  
e-mail: [m.stokkel@nki.nl](mailto:m.stokkel@nki.nl)

Dr. Helle Westergreen Hendel  
Department of Diagnostic Sciences  
Herlev University  
University of Copenhagen  
Copenhagen  
Denmark  
e-mail: [Helle.Westergren.Hendel@regionh.dk](mailto:Helle.Westergren.Hendel@regionh.dk)

Maria Jose Garcia Velloso  
Servicio de Medicina Nuclear  
Clinica Universitaria de Navarra  
Universidad de Navarra  
Pamplona  
Spain  
e-mail: [mjgarciave@unav.es](mailto:mjgarciave@unav.es)

Dr. Evija Olmane  
Department of Radiology  
Pauls Stradins Clinical University Hospital  
Pilsonu 13, Riga, Latvia, LV-1002  
E-mail: [evija.olmane@inbox.lv](mailto:evija.olmane@inbox.lv)

Prof. Dace Baltina  
Latvian chief oncologist at the Latvian Oncology Center  
Riga Eastern Clinical University Hospital  
Hipokrata 4, Riga, Latvia, LV-1079  
Tel: +371 67042005  
E-mail: [dace.baltina@aslimnica.lv](mailto:dace.baltina@aslimnica.lv)

Prof. Sandra Lejniece  
Head of the Department of Chemotherapy and Hematology  
Riga Eastern Clinical University Hospital  
Hipokrata 4, Riga, Latvia, LV-1079  
E-mail: [lejniece@latnet.lv](mailto:lejniece@latnet.lv)

Dr. Donatas Vajauskas  
Head of Nuclear Medicine department  
Radiology and Nuclear medicine center  
Vilnius University Hospital Santariskiu Klinikos  
Santariskiu 2, Vilnius, Lithuania, LT-08661  
Tel.: +370 697 71066  
E-mail: [donatas.vajauskas@santa.lt](mailto:donatas.vajauskas@santa.lt)

Prof. Mirosław Dziuk MD  
Head of the Department of Nuclear Medicine  
Masovian PET/CT Centre  
Military Institute of Medicine  
Szaserów 128, 04-141, Warszawa mazowieckie 04-141, Poland  
E-mail: [mdziuk@wim.mil.pl](mailto:mdziuk@wim.mil.pl)